1. Scrip
  2. >>New Products

Galderma’s Nemluvio Brings New Mechanism To Atopic Dermatitis

 
• By Jessica Merrill

Nemluvio is the first IL-31 inhibitor approved by the US FDA for atopic dermatitis and will compete with Sanofi/Regeneron’s Dupixent and other, newer IL-13 inhibitors.

(Shutterstock)
Key Takeaways
  • Galderma’s Nemluvio was approved by the FDA for atopic dermatitis, a new larger indication for the IL-31 inhibitor previously approved for prurigo nodularis.
  • Nemluvio brings a new mechanism of action to the atopic dermatitis market, which dermatologists say is needed due to the heterogeneous nature of the condition.
  • Galderma has expectations for Nemluvio to become a blockbuster seller by the end of 2027.

Galderma’s Nemluvio (nemolizumab) is the first IL-31 inhibitor approved by the US Food and Drug Administration for the treatment of atopic dermatitis (AD), bringing a new mechanism of action to...

Nemluvio joins several other biologic drugs already on the market for AD but is unique in its mechanism of action, which has demonstrated efficacy on skin clearing and itch relief....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Therapy Areas

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.